Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
Status:
Terminated
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
This research study is looking at the use of the drug ambrisentan and if it can improve right
ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial
hypertension. It is also looking at using right ventricle function changes as a marker of
disease severity.